Page 80 - Read Online

Page 10 of 10 Ruff et al. Hepatoma Res 2023;9:37 https://dx.doi.org/10.20517/2394-5079.2023.51

therapeutic targets. Ann Surg Oncol 2014;21:3827-34. DOI PubMed PMC
30. Boerner T, Drill E, Pak LM, et al. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology 2021;74:1429-
44. DOI PubMed PMC
31. Goyal L, Govindan A, Sheth RA, et al. Prognosis and clinicopathologic features of patients with advanced stage isocitrate
dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma. Oncologist 2015;20:1019-27. DOI PubMed PMC
32. Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One
2014;9:e115383. DOI PubMed PMC
33. Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced
cholangiocarcinoma with idh1 mutation: the phase 3 randomized clinical clarIDHy trial. JAMA Oncol 2021;7:1669-77. DOI PubMed
PMC
34. Cleary JM, Rouaisnel B, Daina A, et al. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired
resistance to ivosidenib in cholangiocarcinoma. NPJ Precis Oncol 2022;6:61. DOI PubMed PMC
35. Lowery MA, Burris HA 3rd, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced
cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol 2019;4:711-20. DOI PubMed PMC
36. NCCN guidelines version: hepatobiliary cancers. 2022. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=
1&id=1438 [Last accessed on 31 Jul 2023].
37. Salama V, Brooks N, Skwarska A, et al. Abstract 6417: LY3410738, a novel inhibitor of mutant IDH1 is more effective than
Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML).
Cancer Res 2020;80:6417. DOI
38. Pauff JM, Papadopoulos KP, Janku F, et al. A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in
cholangiocarcinoma and other advanced solid tumors. J Clin Oncol 2021;39:TPS350. DOI
39. Wang Y, Wild AT, Turcan S, et al. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas
and cholangiocarcinomas. Sci Adv 2020;6:eaaz3221. DOI PubMed PMC
40. Schvartzman JM, Reuter VP, Koche RP, Thompson CB. 2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing
H3K9 demethylation. Proc Natl Acad Sci U S A 2019;116:12851-6. DOI PubMed PMC
41. Sharma H. Development of novel therapeutics targeting isocitrate dehydrogenase mutations in cancer. Curr Top Med Chem
2018;18:505-24. DOI PubMed
42. Stewart MD, Merino Vega D, Arend RC, et al. Homologous recombination deficiency: concepts, definitions, and assays. Oncologist
2022;27:167-74. DOI PubMed PMC
43. Niger M, Nichetti F, Casadei-Gardini A, et al. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic
cholangiocarcinoma: a propensity score-based study. Int J Cancer 2022;151:1310-20. DOI
44. Saha SK, Gordan JD, Kleinstiver BP, et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence
in intrahepatic cholangiocarcinoma. Cancer Discov 2016;6:727-39. DOI PubMed PMC
45. Fujiwara H, Tateishi K, Kato H, et al. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET
inhibitor JQ1. Cancer Sci 2018;109:3602-10. DOI PubMed PMC
46. Zeng L, Zhou MM. Bromodomain: an acetyl-lysine binding domain. FEBS Lett 2002;513:124-8. DOI PubMed
47. Choe S, Wang H, DiNardo CD, et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant
relapsed or refractory AML. Blood Adv 2020;4:1894-905. DOI PubMed PMC
48. Wang F, Morita K, DiNardo CD, et al. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute
myeloid leukemia. Nat Commun 2021;12:2607. DOI PubMed PMC
49. Harding JJ, Lowery MA, Shih AH, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase
inhibition. Cancer Discov 2018;8:1540-7. DOI PubMed PMC